ID
28789
Description
Study part: Indirect Ophthalmoscopy Month 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.
Keywords
Versions (1)
- 2/4/18 2/4/18 -
Copyright Holder
Roche
Uploaded on
February 4, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Indirect Ophthalmoscopy Month 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g
Indirect Ophthalmoscopy Month 12
- StudyEvent: ODM
Description
RETINAL BREAK OR DETACHMENT RIGHT EYE
Alias
- UMLS CUI-1
- C0035305
- UMLS CUI-2
- C0229089
Description
retinal break
Data type
text
Alias
- UMLS CUI [1]
- C0035321
Description
retinal detachment
Data type
text
Alias
- UMLS CUI [1]
- C0035305
Description
Serous detachment of the macula
Data type
boolean
Alias
- UMLS CUI [1]
- C1328517
Description
RETINAL BREAK OR DETACHMENT LEFT EYE
Alias
- UMLS CUI-1
- C0035305
- UMLS CUI-2
- C0229090
Description
retinal break
Data type
text
Alias
- UMLS CUI [1]
- C0035321
Description
retinal detachment
Data type
text
Alias
- UMLS CUI [1]
- C0035305
Description
Serous detachment of the macula
Data type
boolean
Alias
- UMLS CUI [1]
- C1328517
Similar models
Indirect Ophthalmoscopy Month 12
- StudyEvent: ODM
C0229089 (UMLS CUI-2)
C2986440 (UMLS CUI [1,2])
C0229089 (UMLS CUI-2)
C0229090 (UMLS CUI-2)
No comments